Status:
COMPLETED
Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease
Lead Sponsor:
Xuanwu Hospital, Beijing
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether Lingzhi (Ganoderma), a widely used traditional Chinese Medicine is effective and safe in the treatment of Parkinson's disease when combined use with L...
Detailed Description
This study is to focus on the effects of Lingzhi on non-motor symptoms of Parkinson's diseases as the primary outcome and on delaying the disease progression using the delay start design as the second...
Eligibility Criteria
Inclusion
- willing and able to give informed consent
- age 30 years or older at time of diagnosis of Parkinson's disease
- have idiopathic Parkinson's disease, defined as:
- having at least 2 of the following 4 signs: resting tremor, bradykinesia, rigidity, or postural reflex impairment, at least one of which must be resting tremor or bradykinesia
- no secondary or atypical parkinsonism
- asymmetric features (current signs or history of asymmetric onset)
- response to L-dopa, by patient self-report
- Parkinson's disease duration of no more than 5 years
- receiving stable therapy of L-dopa/DCI for at least 3 months; acceptable dose range: 250 mg - 1000 mg L-dopa/DCI daily
- Hoehn and Yahr stage \< 4 on stable L-dopa/DCI treatment
Exclusion
- have atypical parkinsonism due to drugs, metabolic disorders, encephalitis, or other neurodegenerative diseases
- have any other known medical or psychiatric condition that may compromise their participation in the study
- have taken another investigational drug within 90 days of baseline
- have a change in dosage of any other antiparkinsonian drug (eg, pramipexole, ropinirole, pergolide, bromocriptine, methylphenidate, anticholinergics, or amantadine) during the study or within 90 days prior to baseline
- have received treatment with dopamine blocking agents (including neuroleptic agents, antiemetic agents), dopamine-depleting agents (including reserpine or tetrabenazine) within 90 days prior to baseline
- do not consent to participate
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2008
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00224263
Start Date
September 1 2005
End Date
February 1 2008
Last Update
August 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital
Beijing, China